Ticker

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its potential as therapeutic solution for a diverse spectrum of patients with hypertriglyceridemia (HTG). The data were presented by Dr. Christie M. Ballantyne, MD, professor at…

Arrowhead Pharmaceuticals transitions from a 'show-me' pipeline to commercial stage, with its first approval for plozasiran in FCS. ARWR's valuation reflects a 5% downside, 10-15% base case upside, and up to 40% bull case upside, supporting a cautious buy rating. The investment thesis centers on a robust RNAi platform, late-stage cardiometabolic franchise, and significant near-term catalysts, notably SHTG phase 3…

Arrowhead Pharmaceuticals (NASDAQ: ARWR) outlined a slate of expected clinical data updates during a discussion at the Leerink Partners Global Healthcare Conference in Miami, with management pointing to multiple readouts concentrated in the third quarter and additional updates expected in the second half of the year. Multiple clinical catalysts expected in the third quarter Chief Executive

Citigroup Inc. decreased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 63.4% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,582 shares of the biotechnology company's stock after selling 89,204 shares during the period. Citigroup Inc.'s holdings in